- Home
- XNCR
XNCR
Xencor Inc.
as 05-15-2025 4:00pm EST
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 568.3M | IPO Year: | 2013 |
| Target Price: | $30.13 | AVG Volume (30 days): | 970.6K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.16 - $27.24 | Next Earning Date: | 05-07-2025 |
| Revenue: | $127,228,000 | Revenue Growth: | -25.88% |
| Revenue Growth (this year): | -0.99% | Revenue Growth (next year): | 25.05% |
Stock Insider Trading Activity of Xencor Inc. (XNCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Valente Nancy | XNCR | EVP, Chief Development Officer | May 2 '25 | Sell | $11.03 | 4,616 | $50,914.48 | 49,169 | |
| Cornelissen Bart Jan | XNCR | SR. VICE PRESIDENT & CFO | Apr 10 '25 | Sell | $8.06 | 3,750 | $30,232.87 | 61,348 | |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Mar 10 '25 | Sell | $13.60 | 19,716 | $268,080.42 | 465,419 | |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Mar 10 '25 | Sell | $13.60 | 9,697 | $131,851.08 | 236,574 | |
| Eckert Celia | XNCR | SVP, GENERAL COUNSEL | Mar 10 '25 | Sell | $13.60 | 5,740 | $78,047.35 | 63,507 | |
| Valente Nancy | XNCR | EVP, Chief Development Officer | Mar 10 '25 | Sell | $13.60 | 2,565 | $34,876.56 | 49,169 |
Latest Xencor Inc. News
XNCR Breaking Stock News: Dive into XNCR Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
XNCR: What does Argus have to say about XNCR?
Zacks
8 days ago
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
8 days ago
Xencor: Q1 Earnings Snapshot
Business Wire
8 days ago
Xencor Reports First Quarter 2025 Financial Results
Argus Research
9 days ago
XNCR: Lowering target price to $9.00
Zacks
14 days ago
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
Business Wire
16 days ago
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Argus Research
23 days ago
XNCR: Raising target price to $11.00
Compare XNCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XNCR Xencor Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.